Quoin Pharmaceuticals
QNRX
4 hedge funds and large institutions have $573K invested in Quoin Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
95% more capital invested
Capital invested by funds: $294K → $573K (+$279K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$359K |
| 2 |
Renaissance Technologies
New York
|
+$179K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$179K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$179K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$62K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $214K | +$359K | +2 | New |
|
|
2
Renaissance Technologies
New York
| $148K | +$179K | +1 | New |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $78K | +$179K | +1 | New |
|
|
WS
4
Wedbush Securities
Los Angeles,
California
| $66K | +$179K | +1 | New |
|
5
Morgan Stanley
New York
| $18K | – | – | – |
|
|
TSS
6
Two Sigma Securities
New York
| $15K | – | – | – |
|
|
SIGI
7
Susquehanna International Group (Ireland)
Dublin,
Ireland
| $12K | – | – | – |
|
|
RJFSA
8
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| $11K | – | – | – |
|
9
Citigroup
New York
| $10K | – | – | – |
|
10
UBS Group
Zurich,
Switzerland
| $1K | – | – | – |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$62K | – | – |
|
QNRX Hedge Fund Activity: Q1 2019 in Review
4 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q1 2019, worth a combined $573K — up 95% from $294K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new QNRX positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $359K. The largest seller was Citadel Advisors, cutting an estimated $62K.
- 4 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q1 2019, up from 0 in Q4 2018.
- Funds reported $573K of Quoin Pharmaceuticals stock for Q1 2019, up 95% quarter-over-quarter.
- 4 funds opened new Quoin Pharmaceuticals positions in Q1 2019 and 0 closed out, a net change of +4 holders.
- The largest Quoin Pharmaceuticals buyer in Q1 2019 was Sabby Management, an estimated $359K added.
- The largest Quoin Pharmaceuticals seller in Q1 2019 was Citadel Advisors, an estimated $62K sold.
Based on aggregated 13F filings for Q1 2019.